Lazertinib

Lazcluze 240 MG Comprimidos Recubiertos con Pelicula

240 mg comprimido recubierto con películaSpainMarketedAuthorised 29 Jan 2025

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

LazcluzeEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Lazertinib

Lazcluze 240 MG Comprimidos Recubiertos con Pelicula

240 mg comprimido recubierto con películaSpainMarketedAuthorised 29 Jan 2025

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

LazcluzeEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Lazcluze 240 mg filmomhulde tablettenNetherlands · Filmomhulde tablet · Janssen-Cilag International NV

Lazcluze 80 mg filmomhulde tablettenNetherlands · Filmomhulde tablet · Janssen-Cilag International NV

Lazcluze Film-coated Tablets 240mgSingapore · 240 mg · tablet, film coated · Johnson & Johnson International (Singapore) Pte LTD

Lazcluze Film-coated Tablets 80mgSingapore · 80 mg · tablet, film coated · Johnson & Johnson International (Singapore) Pte LTD

Lazcluze film-coated tablets 240 mgTaiwan · 膜衣錠 · 嬌生股份有限公司

Lazcluze film-coated tablets 80 mgTaiwan · 膜衣錠 · 嬌生股份有限公司

LazcluzeUnited States · 240MG BASE, 80MG BASE · tablet · Janssen Biotech

Packs

Pack	Code	Status
LAZCLUZE 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidos	766763

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Lazertinib
Strength: 240 mg
Dosage form: comprimido recubierto con película
Route: vía oral
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 29 Jan 2025
Registration: 1241886005
Marketing authorisation holder: Janssen-Cilag International N.V
Procedure: EU centralised
Supply: Diagnóstico Hospitalario
EU number: EU/1/24/1886